Cerulean Pharma Inc. (CERU) announced Monday morning that it has entered into a definitive stock purchase agreement with privately-held Daré Bioscience through which equityholders of Daré Bioscience will become the majority owners of Cerulean.
Cerulean Pharma has gapped open sharply lower this morning and is now down 2.09 at $1.23 on above average volume. The stock has dropped to a 3-week low.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org